Nimbus Synergies Catalyzes BC-Based Health Innovation with New GENERATOR Startup Hub

Nimbus Synergies, a leading Canadian early-stage health technology investor and mentor to Canada's most promising health tech entrepreneurs, is excited to announce the GENERATOR’s relocation to new office space situated on the corner of West Broadway and Oak. This physical move marks the most significant strategic change in the GENERATOR’s 12-year history as it shifts focus to nurturing health tech startups exclusively. This unique 5,000 sqft startup hub, remains a rent-free co-working space, dedicated to providing support for early-stage startups, fostering a thriving health innovation ecosystem in British Columbia.

The new space at 1001 West Broadway, scouted by Alain Rivere of the High Technologies Facilities Group of CBRE, features a spacious open plan layout, abundant natural light, and a captivating outdoor deck with stunning views of Vancouver. The location offers proximity to leading health research organizations including Vancouver General Hospital, BC Cancer Agency, Genome BC, and BC Centre for Disease Control and is anticipated to be ready for occupancy by the end of the year.

"We are thrilled to announce our move to this new space," stated Paul Geyer, CEO at Nimbus Synergies. "The narrowing of focus to health tech ventures aligns with Nimbus’ vision to build a globally recognized health technology ecosystem in BC through leadership, investment, mentorship, philanthropy, and space. We extend a warm invitation to health tech startups based in BC to connect with us and explore the potential opportunities within our new GENERATOR space."

To better serve its constituents, Nimbus Synergies has replaced the competition-based selection process with a curated approach to identify and select companies in need of space and poised to benefit from the shared resources and expertise within the GENERATOR, especially underrepresented founders. This robust selection process will help foster a diverse and interconnected community of complementary and forward-thinking startups.

In anticipation of the move, the GENERATOR has also shifted to a flexible workspace model in response to the prevalence of hybrid work arrangements adopted by most companies. The incorporation of hotdesking and bookable private offices ensures the optimal utilization of the space and increases the opportunity for synergistic interactions and collaborations amongst resident startups.

Nimbus Synergies is dedicated to fostering an inclusive, welcoming workspace for diverse founders to learn and grow from each other. For more information or to be considered for the GENERATOR program, please email arushi@nimbusinc.vc.

ABOUT NIMBUS SYNERGIES

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.

ABOUT THE GENERATOR

The GENERATOR, established in 2011 through partnership with the City of Vancouver, provides promising BC-based health tech startups with access to a rent-free modern co-working space, networking opportunities, and partner programming. The 5,000 sqft startup hub includes unlimited coffee (and tea!), high-speed fiber internet, bookable hot-desks, boardrooms, meeting rooms, and more.

 

Nimbus Synergies Leads Investment in MetaOptima to Accelerate FDA Approval and US Market Adoption of its AI-Powered Skin Diagnostics Platform

Nimbus Synergies, a leading Canadian early-stage health technology investor, has led a $2.6 million investment in MetaOptima Technology, a digital health company that is revolutionizing the dermatology and skin care industry with affordable, effective, and intelligent AI-driven solutions. Existing investors, including Skip Capital and AirTree Ventures, also contributed to the funding round. In addition to this, MetaOptima also received a $2 million investment from WD Business Scale Up program ramping up the total capital raised to over $4.6 million.

DermEngine AI, MetaOptima's latest product, utilizes its proprietary database of more than 2.7 million patients and 10 million images to enable early identification of skin cancer with the power of AI. By accurately detecting skin cancers, DermEngine AI helps healthcare providers save lives and avoid unnecessary procedures, leading to improved patient outcomes. Additionally, the tool has the potential to significantly reduce costs and improve patient experience by eliminating the need for biopsies that are often unnecessary. Research has demonstrated that the rate of such biopsies in primary care centers in the US is as high as 92%. DermEngine AI addresses this issue effectively, making it a valuable addition to the field of skin cancer identification.

Proceeds from the financing will be used to accelerate and achieve US FDA approval for DermEngine AI following the completion of MetaOptima’s latest clinical study. DermEngine AI is a software product that leverages MetaOptima’s existing software and is compatible with MetaOptima’s dermatoscopes, including the MoleScope™. It is designed to help healthcare professionals diagnose skin problems efficiently, generate treatment options intelligently, and monitor efficacy seamlessly.

“We're excited to partner with MetaOptima in their mission to revolutionize the dermatology industry with AI-powered solutions,” said Paul Geyer, CEO of Nimbus Synergies. “MetaOptima’s innovative technology and extensive datasets have the potential to transform the field of dermatology by fast-tracking diagnosis, reducing the time and expense of unnecessary biopsies, and improving patient outcomes. We look forward to working closely with MetaOptima's team to help achieve these goals.”

As part of the investment, Paul Geyer will join MetaOptima's Board of Directors, bringing his extensive entrepreneurial and health technology experience to the company.

“The dermatology and skin cancer treatment industries are facing significant challenges, including limited access to specialized care, high costs, and long wait times,” said Dr. Maryam Sadeghi, CEO and Co-Founder of MetaOptima. “We're thrilled to have the support of Nimbus Synergies to accelerate our mission of making dermatology more accessible and accurate. With their help, we can bring our life-saving tools to millions more patients worldwide.”

 

ABOUT NIMBUS SYNERGIES
Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.


ABOUT METAOPTIMA
MetaOptima is an innovative digital health and AI company based in Vancouver, Canada that strives to empower users with AI technologies to lead a healthier, happier life. MetaOptima is dedicated to revolutionizing the dermatology and skin care industry with effective, affordable, and intelligent tools.  The MetaOptima team not only takes pride in a bold vision to save lives and contribute to better healthcare outcomes, they also work hard to build a successful company, creating jobs and developing tools that make the world a better place for patients, doctors and businesses alike.